Preclinical Imaging Market

Increased demand for certified Preclinical Imaging products to propel market growth

According to the OECD, Governments in the 33 OECD nations budgeted a total of about USD 67 billion for R&D in the health sector in 2018. Moreover, according to the statistics Science and Engineering Indicators, Based on R&D expenditures, a small number of nations handle the majority of R&D. About half of the world's R&D was carried out in 2019 by the United States (27% or $656 billion) and China (22% or $526 billion). South Korea (4%), Germany (6%), and Japan (7% each) also contributed significantly.

Other top performers, like France, India, and the United Kingdom, make up between 2% and 3% of the total. Thus, as the R&D spending increased, the demand for equipment used for imaging in these studies was also fuelled. This factor is driving the market CAGR.

For many years, using animal models has been essential in developing safe therapeutics for patients. These models, however, have the challenging task of roughly simulating the human body, and they frequently fall short. 90% of drugs that fail in Phase 1 clinical trials do so because of toxicity, including inarigivir and many other drugs. To overcome this barrier, companies are continuously advancing their equipment such that they can perform more effective trials. Preclinical imaging is essential for drug discovery, phenotyping, and gaining a fundamental understanding of disease mechanisms. It is difficult to adapt imaging techniques from humans to small animals.

Imaging methods are used more frequently in oncology clinical trials to provide information for making decisions. Key study endpoints are increasingly defined using traditional morphological imaging methods and standardized response criteria based on tumor size measurements. Primary, secondary, and exploratory study endpoints are largely produced by non-invasive imaging techniques like computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Thus, the growing use of preclinical imaging is one of the key factors boosting the Preclinical Imaging market revenue globally.

The shift towards personalized medicine significantly influences the Global Preclinical Imaging Market Industry. Researchers are increasingly utilizing imaging technologies to tailor treatments to individual patient profiles, thereby enhancing therapeutic efficacy. This approach necessitates advanced imaging techniques that can provide detailed insights into disease mechanisms and treatment responses. As the healthcare landscape evolves, the demand for preclinical imaging solutions that support personalized medicine is likely to rise. This trend not only drives market growth but also encourages collaboration between imaging technology providers and pharmaceutical companies, fostering innovation in drug development.

The Global Preclinical Imaging Market Industry benefits from heightened investment in drug development, particularly in the biopharmaceutical sector. Pharmaceutical companies are increasingly allocating resources to preclinical studies to ensure the safety and efficacy of new drugs before they reach clinical trials. This trend is supported by government initiatives aimed at fostering innovation in healthcare. The influx of funding is likely to drive demand for advanced imaging technologies, as they are integral to the drug development process. Consequently, the market is poised for growth, with projections indicating a significant rise in revenue as companies seek to optimize their research and development efforts.

The Global Preclinical Imaging Market Industry experiences a notable increase in demand for non-invasive imaging techniques. These methods, such as MRI and PET, allow researchers to observe biological processes in real-time without the need for invasive procedures. This trend is driven by the growing emphasis on ethical research practices and the need for accurate data in drug development. As a result, the market is projected to reach 4.97 USD Billion in 2024, reflecting a shift towards more humane and effective research methodologies. The adoption of these technologies is likely to enhance the efficiency of preclinical studies, thereby accelerating the drug discovery process.

Regulatory bodies worldwide are increasingly recognizing the importance of preclinical research in the drug development process, which positively impacts the Global Preclinical Imaging Market Industry. Supportive regulations and guidelines facilitate the use of advanced imaging technologies in preclinical studies, ensuring that safety and efficacy are thoroughly evaluated before clinical trials. This regulatory environment encourages investment in imaging solutions, as companies seek to comply with stringent standards. As a result, the market is expected to experience steady growth, driven by the need for reliable preclinical data that meets regulatory requirements.

Technological innovations play a crucial role in shaping the Global Preclinical Imaging Market Industry. The introduction of advanced imaging modalities, such as high-resolution optical imaging and hybrid imaging systems, enhances the capabilities of researchers to visualize complex biological phenomena. These advancements not only improve image quality but also increase the speed of data acquisition. As a result, the market is expected to grow at a CAGR of 6.46% from 2025 to 2035, potentially reaching 9.89 USD Billion by 2035. This growth is indicative of the ongoing commitment to improving imaging technologies, which are essential for effective preclinical research.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Preclinical Imaging market accounted for USD 36.4 billion in 2022, with a share of around 45.80%, and is expected to exhibit a significant CAGR growth during the study period. Higher adoption rates of technologically advanced devices in the area, developed infrastructure, and a large number of preclinical projects. The region's greater adoption of technologically advanced devices, the accessibility of skilled professionals, the volume of preclinical projects, and so forth.

New clinical research and development projects are also being encouraged by government initiatives in this region.

Further, the major countries studied in the market report are: The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: PRECLINICAL IMAGING MARKET SHARE BY REGION 2023 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Preclinical Imaging market accounts for the second-largest market share. In-vivo imaging systems are becoming more widely used in Preclinical research due to the growing number of clinical research organizations (CROs) and pharmaceutical companies, further accelerating the growth of this market. Moreover, the UK market of preclinical Imaging held the largest market share, and the Germany market of preclinical Imaging was the fastest-growing market in the region.

Asia Pacific Preclinical Imaging Market is expected to grow at the fastest CAGR from 2024 to 2032. The region is becoming more appealing for preclinical research studies due to low research costs, laxer regulatory requirements, and increased government funding for developing the research and development sector in the respective countries. Moreover, The factors attributing to the market development include expanded public-private initiatives, innovative advances in molecular imaging, and expanded market interest in non-intrusive small animal imaging methods. Further, the China market of preclinical Imaging held the largest market share, and the India market of preclinical Imaging was the fastest-growing region.

Major market players are investing & funding to support the R&D activities such that they can launch new medicines in the market. Companies are also taking initiatives to grow their market share, with key market developments such as new product launches, increased investments, growing product pipelines, and collaboration with other companies. The government constantly supports players in the Preclinical Imaging industry to launch new products.

Several start-up companies are also entering the Preclinical Imaging industry by raising funds to develop their products. The Preclinical Imaging markets major player such as Bruker Corporation (US), MR Solutions (UK), PerkinElmer (US), Fujifilm Holdings Corporation (Japan), Milabs B.V. (The Netherlands), Mediso Ltd. (Hungary), Miltenyi Biotec GmbH (Germany), LI-COR Inc. (US), Aspect Imaging (Israel), and Trifoil Imaging (US) are launching new products in the market.

Bruker Corporation (US) is a life science research and diagnostics solutions company dedicated to researching and providing solutions for the healthcare sector. In May 2022, Tesla Bruker announced the launch of innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets. The new range of Maxwell 7 Tesla and 9.4 Tesla magnets is anticipated to follow its BioSpec Maxwell 3 Tesla model's success, eliminating the need for liquid Helium or Nitrogen refills while providing high-field sensitivity and resolution for cutting-edge preclinical MRI and PET/MR research.

PerkinElmer (US) is one of the top manufacturers of preclinical imaging systems, including the widely used IVIS optical imaging platform. These systems cover a variety of modalities, including ultrasound, optical, and micro CT. In April 2022, PerkinElmer introduced the Vega imaging system. This first-of-its-kind ultrasound platform combines hands-free, automated technology with the high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology, and more.